CA-PERSONALIS,-INC.
18.11.2020 14:02:04 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy , a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
Poster Number |
Title & Presenter |
Dates |
||
40
|
Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
|
NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
Title |
Title & Presenter |
Dates |
||
Sponsored Symposia |
NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
|
NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
Credit Derivatives Determinations Committees Membership applications for 202627.3.2026 17:30:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Friday, April 3, 2026. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-commit
Andersen Consulting indgår samarbejdsaftale med Solutia27.3.2026 15:22:00 CET | Pressemeddelelse
Andersen Consulting udvider sin tilstedeværelse i Spanien gennem en samarbejdsaftale med Solutia, en virksomhed med speciale i løsninger inden for arbejdsmiljø og sundhed samt rekruttering inden for life science- og sundhedssektoren. Solutia blev stiftet i 2014 og tilbyder omfattende tjenester og rådgivning med fokus på sunde arbejdsmiljøer, sygefravær, outsourcing af sundhedsydelser og uddannelse til organisationer på tværs af alle sektorer. Virksomheden leverer også rekrutterings- og executive search-løsninger med fokus på life science, tekniske fagfolk samt mellem- og topledelse samt dybdegående ekspertise inden for medicinal-, bioteknologi-, medico- og sundhedsindustrien. Ved hjælp af datadrevne og skræddersyede løsninger hjælper Solutia virksomheder med at optimere medarbejdereffektiviteten og tiltrække specialister. "Vores mål er at forbedre, hvordan organisationer tiltrækker, udvikler og leder medarbejdere i et stadig mere komplekst miljø," udtalte Cesar Castel, administrerende
Klarna Partners With EuroParcs to Offer Flexible Payments for Holiday Park Stays Across Europe27.3.2026 15:04:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, today announces a new partnership with EuroParcs, one of Europe's fastest-growing holiday park operators. The collaboration gives holidaymakers in Germany, the Netherlands, Belgium, and Austria more flexibility in how they pay for their getaway. Guests booking through EuroParcs can now choose from a range of Klarna payment options tailored to their market: Germany & Austria: Pay in Full, Pay in 30 Days, Pay in 3, and Financing Netherlands: Pay in Full, Pay in 30 Days, and Pay in 3 Belgium: Pay in Full and Pay in 30 Days Nicole Defren, Head of Europe at Klarna, says: "Booking a holiday should feel exciting, not complicated – and that includes how you pay for it. With Klarna, EuroParcs guests can choose the payment option that suits them best, whether that's paying upfront, in a few weeks, or spreading the cost over time. From a cosy chalet on the Veluwe to a luxury villa in the Austrian Alps, we're making it easier for fami
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom